Download MendeleyExploiting the Cryptic alpha D Pocket of Casein Kinase 2 alpha (CK2 alpha ) to Deliver Highly Potent and Selective Type 1 Inhibitors.
Glossop, P.A., Brear, P., Wright, S., Flanagan, N., Glossop, M.S., Lane, C.A.L., Butt, R.P., Spring, D.R., Hyvonen, M., Cawkill, D.(2025) J Med Chem 68: 21587-21614
- PubMed: 41085029 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.5c01807
- Primary Citation Related Structures:
9QQX, 9QY7 - PubMed Abstract:
Casein kinase 2α (CK2α) is an oncology drug target that acts as a positive regulator of many tumorigenic signaling pathways. We previously reported that CK2α has a unique cryptic binding site, the αD pocket, that offers the potential for inhibitors with improved kinase selectivity. The prototype bivalent molecule CAM4066 ( 6 ) confirmed that improved selectivity could be achieved while binding in both the ATP-binding site and the αD pocket. A drug discovery project to develop a new series of bivalent CK2α inhibitors with increased cell potency and selectivity identified 61f (APL-5125), a highly potent, ATP-competitive CK2α inhibitor with exquisite kinase selectivity and cellular potency. Compound 61f demonstrates in vivo inhibition of p-AKT S129 in tumors (HCT116) following once-daily oral administration and shows a clear PK-PD relationship with unbound drug exposure. 61f has a superior preclinical profile to existing CK2α inhibitors and is currently under evaluation in patients with advanced solid tumors.
- Sandexis Medicinal Chemistry Ltd, Discovery Park, Ramsgate Road, Sandwich, Kent CT13 9FF, U.K.
Organizational Affiliation:
